CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

Table 4 CRISPR/Cas9 applications in CAR-T cell therapy

Cancer	Target locus	Cell/animal	Delivery method	CAR	Ref.
Ewing sarcoma	EZH2	VH-64, RM-82, and WE-68 cell lines Mice	Lentivirus	GD2	[317]
Lymphoma	LAG-3	K562 and Raji cell lines Mice	Plasmid	CD19	[244]
Leukemia	TRAC	MOLT-3, MOLT-4, HSB-2, and CCRF-CEM cell lines	Electroporation	CD7	[318]
Glioma	DGK	U87MGvIII cell line Mice	Lentivirus	EGFRvIII	[319]
Leukemia	GM-CSF	Nalm-6 cell line	Lentivirus	CD19	[250]
Glioma	PD1	U87MGvIII cell line Mice	Electroporation	CD133	[242]
Solid tumors	TGFβRII	HepG2 cell line Mice	Electroporation	Mesothelin	[245]
Lymphoma	TRAC PD-1	NALM6 cells	Electroporation	CD22	[320]
Leukemia Prostate cancer	TRAC, TRBC, FAS, CTLA-4 B2M, PD1	Mice	Electroporation	PSCA, CD19	[321]
Glioma	PD1	U-251MG and Ev-DKMG cell lines	Plasmid	EGFRvIII	[322]
Leukemia	TRAC	Mice	Electroporation	CD19	[323]
Solid tumors	A2AR	E0771, 24JK, MC38, VCAR-3, MCF7, and MDA-MB-435 cell lines	Electroporation	Lewis HER2	[324]

Lymphocyte-activation gene 3 (LAG-3), granulocyte–macrophage colony-stimulating factor (GM-CSF), epidermal growth factor receptor variant III (EGFR vIII), transforming growth factor-beta receptor II (TGFβRII), A2A adenosine receptor (A2AR), prostate stem cell antigen (PSCA), enhancer of zeste homolog 2 (EZH2), diacylglycerol kinase (DGK), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell receptor alpha/B constant (TRAC/TRBC), beta-2-microglobulin (B2M), human epidermal growth factor receptor 2 (HER2), programmed cell death protein 1 (PDCD1 or PD1)

ISSN: 1689-1392